Daniel J. George, MD, on RCC: Results From the Alliance A031203 CABOSUN Trial

2018 Genitourinary Cancers Symposium
Tweet this page

Daniel J. George, MD, of Duke University Medical Center, discusses study findings on cabozantinib vs sunitinib for previously untreated patients with advanced renal cell carcinoma of intermediate or poor risk, in a subgroup analysis of progression-free survival and objective response rates (Abstract 582).

Advertisement

Advertisement



Advertisement